CY1113253T1 - Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη - Google Patents

Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη

Info

Publication number
CY1113253T1
CY1113253T1 CY20121101012T CY121101012T CY1113253T1 CY 1113253 T1 CY1113253 T1 CY 1113253T1 CY 20121101012 T CY20121101012 T CY 20121101012T CY 121101012 T CY121101012 T CY 121101012T CY 1113253 T1 CY1113253 T1 CY 1113253T1
Authority
CY
Cyprus
Prior art keywords
progesterone
brain injury
traumatic brain
dosage regimen
therapeutic treatment
Prior art date
Application number
CY20121101012T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellermann
Donald G Stein
David W Wright
Douglas W Lowery-North
Sarah Melissa Cutler
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of CY1113253T1 publication Critical patent/CY1113253T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Μέθοδοι θεραπευτικής αντιμετώπισης ενός ατόμου με τραυματική βλάβη του κεντρικού συστήματος, πιο συγκεκριμένα με μια τραυματική εγκεφαλική βλάβη. Οι μέθοδοι περιλαμβάνουν μια θεραπεία που αποτελείται από ένα σταθερό ή ένα δοσολογικό σχήμα δυο σταδίων χορήγησης προγεστερόνης. Σε μια μέθοδος, σε έναν ασθενή με την ανάγκη αυτού χορηγείται τουλάχιστον ένας κύκλος θεραπείας, που περιλαμβάνει τη χορήγηση ενός θεραπευτικά δραστικού ενδοφλέβιου δοσολογικού σχήματος προγεστερόνης. Το δοσολογικό σχήμα δυο σταδίων περιλαμβάνει μια πρώτη χρονική περίοδο, κατά την οποία χορηγείται στο άτομο μια υψηλότερη ωριαία δόση προγεστερόνης, ακολουθούμενη από μια δεύτερη χρονική περίοδο, κατά την οποία χορηγείται στον ασθενή μια χαμηλότερη ωριαία δόση προγεστερόνης.
CY20121101012T 2005-03-24 2012-10-25 Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη CY1113253T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24
EP06748657A EP1868614B1 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone

Publications (1)

Publication Number Publication Date
CY1113253T1 true CY1113253T1 (el) 2016-04-13

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100496T CY1111478T1 (el) 2005-03-24 2011-05-20 Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
CY20121101012T CY1113253T1 (el) 2005-03-24 2012-10-25 Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100496T CY1111478T1 (el) 2005-03-24 2011-05-20 Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης

Country Status (16)

Country Link
US (4) US20090221544A1 (el)
EP (5) EP1868614B1 (el)
JP (5) JP5295755B2 (el)
AT (2) ATE520404T1 (el)
AU (2) AU2006226811B2 (el)
CA (2) CA2602950C (el)
CY (2) CY1111478T1 (el)
DE (1) DE602006020353D1 (el)
DK (2) DK2030622T3 (el)
ES (2) ES2428313T3 (el)
HK (3) HK1112579A1 (el)
HR (2) HRP20110198T1 (el)
PL (2) PL1868614T3 (el)
PT (2) PT1868614E (el)
RS (1) RS52471B (el)
WO (2) WO2006102644A2 (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2052724A1 (en) * 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
EP2260052A4 (en) 2008-02-26 2013-01-16 Univ Emory STEROIDANALOGA FOR NEUROPROTEKTION
AU2009293164B2 (en) 2008-09-18 2015-07-09 Northwestern University NMDA receptor modulators and uses thereof
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
EP2533799B8 (en) 2010-02-08 2019-12-25 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
JP6035326B2 (ja) * 2011-04-27 2016-11-30 ノースウェスタン ユニバーシティ アルツハイマー病、ハンチントン病、自閉症及びその他の疾患を治療する方法
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
BR112014018110B1 (pt) * 2012-01-23 2022-06-07 Sage Therapeutics, Inc Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
CN104136007A (zh) 2012-02-29 2014-11-05 贝朗医疗有限公司 含有激素的包含磷虾磷脂的乳液
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
KR102305359B1 (ko) * 2012-08-21 2021-09-24 세이지 테라퓨틱스, 인크. 간질 또는 간질지속 상태를 치료하는 방법
CA2892811A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20151438A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
DK3033350T3 (da) 2013-08-12 2021-08-30 Univ Emory Progesterone fosfatanaloger og anvendelser relateret dertil
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
CN109414444A (zh) 2016-03-08 2019-03-01 萨奇治疗股份有限公司 神经活性类固醇、其组合物及用途
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
SG11201900551WA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
PE20190502A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
WO2023102149A1 (en) * 2021-12-02 2023-06-08 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
NZ512334A (en) * 1993-01-19 2005-05-27 Endorech Inc Therapeutic methods and delivery systems utilizing sex steroid precursors
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
AU7569194A (en) * 1993-08-20 1995-03-21 Meyer B. Jackson Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
BR9608592A (pt) * 1995-06-06 1999-06-29 Cocensys Inc Esteróides neuroativos da série do androstano e do pregnano
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
AU3136897A (en) 1996-05-22 1997-12-09 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
BR9809376A (pt) 1997-05-02 2000-07-04 American Home Prod Pregnan-3-ol-20-onas
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns

Also Published As

Publication number Publication date
US20090325920A1 (en) 2009-12-31
DK2030622T3 (da) 2011-05-02
AU2006226811B2 (en) 2010-11-25
PT2030622E (pt) 2011-06-02
EP2494976A1 (en) 2012-09-05
AU2006226811A1 (en) 2006-09-28
ATE520404T1 (de) 2011-09-15
JP2014055183A (ja) 2014-03-27
CA2602950A1 (en) 2006-09-28
EP1868614A2 (en) 2007-12-26
PT1868614E (pt) 2012-11-23
JP2013234191A (ja) 2013-11-21
JP5394059B2 (ja) 2014-01-22
HK1112579A1 (en) 2008-09-12
ES2392454T3 (es) 2012-12-10
JP5496407B2 (ja) 2014-05-21
US8614203B2 (en) 2013-12-24
JP2008534512A (ja) 2008-08-28
AU2006226774B2 (en) 2010-12-02
EP2431042A1 (en) 2012-03-21
JP2011225629A (ja) 2011-11-10
CA2601715C (en) 2012-10-16
JP2008534515A (ja) 2008-08-28
HK1128242A1 (en) 2009-10-23
HRP20120688T1 (hr) 2012-09-30
EP1868614B1 (en) 2012-08-08
US20090221544A1 (en) 2009-09-03
US20120289491A1 (en) 2012-11-15
HRP20110198T1 (hr) 2011-04-30
US20120245133A1 (en) 2012-09-27
WO2006102644A2 (en) 2006-09-28
ES2428313T3 (es) 2013-11-07
AU2006226774A1 (en) 2006-09-28
EP2431042B1 (en) 2013-06-26
EP1871382A2 (en) 2008-01-02
DK1868614T3 (da) 2012-11-12
WO2006102644A9 (en) 2006-11-23
WO2006102644A3 (en) 2007-03-01
WO2006102596A2 (en) 2006-09-28
CA2601715A1 (en) 2006-09-28
PL1868614T3 (pl) 2013-01-31
EP2030622B1 (en) 2011-02-23
HK1112581A1 (en) 2008-09-12
WO2006102596A3 (en) 2007-01-18
CA2602950C (en) 2012-10-30
CY1111478T1 (el) 2015-08-05
EP2030622A1 (en) 2009-03-04
RS52471B (en) 2013-02-28
PL2030622T3 (pl) 2011-07-29
JP5295755B2 (ja) 2013-09-18
EP1871382B1 (en) 2011-08-17
DE602006020353D1 (de) 2011-04-07
ATE499104T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
CY1113253T1 (el) Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη
CY1117916T1 (el) Θεραπεια διαταραχων που σχετιζονται me bdnf χρησιμοποιωντας laquinimod
CY1117357T1 (el) Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεων
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
CY1121288T1 (el) Μεθοδος αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
CY1110013T1 (el) Συνδυασμοι για θεραπεια πολλαπλου μυελωματος
CY1110495T1 (el) Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα
JP2006501240A5 (el)
NO20014519D0 (no) Apomorfin- og sildenafilpreparat
JP2016530280A5 (el)
AR070842A1 (es) Regimen de dosificacion para un agonista de receptor selectivo de s1p1
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2014530873A5 (el)
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
RU2013123646A (ru) Комбинированная композиция
RU2010151660A (ru) Способы лечения множественной миеломы
MX2020010034A (es) Metodo de tratamiento de enfermedad fibrotica.
CY1115269T1 (el) Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
MX2021002090A (es) Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto.
NO20024683L (no) Terapier med oppdelte doser som har vaskulirt skadende aktivitet
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
Green et al. General approach to and summary of the guideline for the management of atopic dermatitis: CME-summary
AR111491A1 (es) Métodos para tratar enfermedades pediátricas